ENTX,Entera Bio Ltd. | Healthcare

Healthcare

ENTX

All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities

Entera Bio Ltd.ENTX

USD

- At close

USD

- Until the end

The complete list of US stocks

MAX

Overview >

Market Cap

76.76M

Revenue (ttm)

181,000

Net Income (ttm)

-9.54M

Shares Out

45.42M

EPS (ttm)

-0.25

PE Ratio

n/a

Forward PE

n/a

Dividend

n/a

Ex-Dividend Date

n/a

Volume

14,990

Open

1.610

Previous Close

1.690

Day's Range

1.610 - 1.695

52-Week Range

1.410 - 3.350

Beta

1.48

Analysts

Strong Buy

Price Target

10.00 (+491.72%)

Earnings Date

May 9, 2025

Description >

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs.

The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures.

Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and hGh for the GH deficiency.

The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses.

Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Latest News >

Murphy USA Q4 Earnings, Revenue Fall; Shares Down After Hours

Feb 5, 2025

04:52 PM EST, 02/05/2025 (MT Newswires) -- Murphy USA ( MUSA ) reported Q4 earnings late Wednesday of $6.96 per diluted share, down from $7 a year earlier. Two analysts polled by FactSet expected $6.67. Operating revenue for the quarter ended Dec. 31 fell to $4.71 billion from $5.07 billion a year earlier. Analysts surveyed by FactSet expected $4.90 billion....

Resmed Insider Sold Shares Worth $484,220, According to a Recent SEC Filing

Feb 5, 2025

04:51 PM EST, 02/05/2025 (MT Newswires) -- Peter C Farrell, Director, on February 05, 2025, sold 2,000 shares in Resmed ( RMD ) for $484,220. Following the Form 4 filing with the SEC, Farrell has control over a total of 77,218 common shares of the company, with 77,218 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/943819/000112760225003232/xslF345X05/form4.xml ...

TotalEnergies CEO doubles down on US LNG, downplays Trump tariff fears

Feb 5, 2025

* Plans to expand Cameron, Rio Grande projects over next decade * CEO says Trump will be pragmatic * Company LNG portfolio can handle trade disruptions * Urges Europe not to ban Russian LNG before 2027 By America Hernandez LONDON, Feb 5 (Reuters) - TotalEnergies will expand its investment in U.S. liquefied natural gas over the next decade as the...

Mid-America Apartment Communities Q4 Core AFFO Declines, Revenue Rises; 2025 Core AFFO Guidance Issued

Feb 5, 2025

04:52 PM EST, 02/05/2025 (MT Newswires) -- Mid-America Apartment Communities ( MAA ) reported late Wednesday Q4 core adjusted funds from operations of $2.03 per diluted share, down from $2.10 a year earlier. Analysts polled by FactSet expected adjusted FFO of $2.03. Rental and other property revenue for the quarter ended Dec. 31 was $549.8 million, up from $542.2 million...